Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. - Wikidata - wikimedia - TriplyDB

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

http://www.wikidata.org/entity/Q34656225

about

Gout: optimizing treatment to achieve a disease cure Cancer cachexia: impact, mechanisms and emerging treatments Eicosapentaenoic acid and oxypurinol in the treatment of muscle wasting in a mouse model of cancer cachexia Allopurinol: insights from studies of dose-response relationships.T cell-mediated hypersensitivity reactions to drugs Allopurinol reduces the lethality associated with acute renal failure induced by Crotalus durissus terrificus snake venom: comparison with probenecid.Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells - Effects on gene expression levels and thiopurine metabolism.The pharmacokinetics of oxypurinol in people with gout.Predicting allopurinol response in patients with gout Consensus guidelines for oral dosing of primarily renally cleared medications in older adults.Management of gout.Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study.Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.Pharmacokinetics considerations for gout treatments.Allopurinol hypersensitivity: investigating the cause and minimizing the risk.Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.Allopurinol induces innate immune responses through mitogen-activated protein kinase signaling pathways in HL-60 cells.Drug Therapy for Stable Angina Pectoris.Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist.Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.Sildenafil protects epithelial cell through the inhibition of xanthine oxidase and the impairment of ROS production.Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors Successful use of allopurinol in a patient on dialysis.Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease.Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics.Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.Rapid determination of the emerging contaminant oxypurinol in surface water using solid phase extraction followed by ultra high-performance liquid chromatography with fluorescence detection.Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.Individualising the dose of allopurinol in patients with gout.The modulatory effects of allopurinol on N-methyl D-aspartate receptors in the central nervous system.Promising effects of xanthine oxidase inhibition by allopurinol on autonomic heart regulation estimated by heart rate variability (HRV) analysis in rats exposed to hypoxia and hyperoxia.Simultaneous analysis of allopurinol and oxypurinol using a validated liquid chromatography-tandem mass spectrometry method in human plasma.Fluoroquinolones and propionic acid derivatives induce inflammatory responses in vitro.Pharmacokinetics and comparative bioavailability of allopurinol formulations in healthy subjects.Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis.Comparison of the effect of allopurinol and febuxostat on urinary 2,8-dihydroxyadenine excretion in patients with Adenine phosphoribosyltransferase deficiency (APRTd): A clinical trial.

P2860

Q26765550-1C222314-1EDC-47FD-9973-93E877475493 Q28384479-C414197F-0AC2-4331-906A-FCBF1FC73252 Q28483912-7FA3AA92-04C3-46F3-AFBB-271E7AFD7E5C Q30240163-9A600E5E-ADB7-4974-A7B6-85D25FC6718E Q34971993-69E32632-EF99-4194-8A9B-81700FB05C85 Q35198815-EE485E03-7BF7-42DA-9FB8-67DB5827A9AB Q35627898-123AF2D2-15A9-4E63-BE21-F47B422EF90F Q36302849-0EAC2791-5953-408B-951A-68C84074F8E1 Q36336035-74AD4FC2-5F55-41D2-A0C2-E60BE9B76BEC Q36802064-A8127B20-B759-44FD-943C-1EBA886B62A0 Q37093020-90B7C591-65EB-4823-80F7-151EEF5081A8 Q37139512-B00AFECB-4601-455E-A3A0-D54E2C865AA7 Q37353448-D7F751C1-BA2E-474C-A03C-F2A2F9CD636A Q37515580-8235FE9D-13B3-4B88-8D5E-B83FD3B617B9 Q37600805-D5EA82BC-CBFB-412C-9133-15CD7D3A3015 Q38123116-A5C375C4-7A5C-4340-89C1-F684D63DA672 Q38210284-5927A533-6241-478A-81E7-BB58AE7AD6E6 Q38594891-A8E046B6-87D4-4EF5-AE2F-8EE9F0B426FD Q38704139-817325BA-610D-4C15-A740-A6F00D5CF1D0 Q38814020-8AE8CEC9-73D9-416C-BD25-E9E654D14BEA Q39102158-A6A55C22-180E-4842-8853-35C56CE32ABF Q39110729-28F08329-D48F-47FD-9F82-C1C2942BC210 Q39278948-5DBEB74C-1E94-48CC-A6EF-D4D31431115E Q39766050-70807A8E-7627-4C53-A006-76FA295617E9 Q41422598-C1EAB97C-5C44-4A04-B557-05A47CADBC65 Q41981175-8590BCE8-0DFE-4C61-BFF3-0437713F0756 Q43230369-5D9ACF04-A8DF-49D5-8AC6-18EF8C40E1A1 Q46076879-A7EF3E07-B417-42B0-A613-227D32D9831F Q46955809-D19AB3FF-D499-47B9-BF59-EBFC6D743E98 Q47848663-028DD9C2-4B14-41DB-9F87-FD4D2636E1CD Q48191847-461FBB28-901B-4D17-B6CC-9D665D0D63CA Q48266996-720F859F-7C30-44BF-ADB5-22CFF3BED0F9 Q48334442-08BB9183-DE33-4914-9A94-D6DB8A9DF6EE Q50047257-9B8E5760-390F-4AD0-8029-8AED71DC1CCE Q50196363-054074B2-AD73-4FA3-87D0-8491D5C0EDC3 Q51101396-07BF8926-A19F-4E85-B046-D63937DFA5B1 Q51316564-628F2112-8A09-4448-9254-FBB30F77AC62 Q51746631-FEEEB640-3F55-4C96-88E7-9B2D317E82B5 Q51790528-D28C763E-C273-4FA5-8DBD-F49F6FF9C3C1 Q52749977-9A1B1020-B1E8-43D8-83F9-FE9A6F5706BA

P2860

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

http://www.wikidata.org/entity/Q34656225

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

@ast

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

@en

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

@nl

type

label

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

@ast

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

@en

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

@nl

prefLabel

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

@ast

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

@en

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

@nl

P1433

Q34656225-294688C0-6494-4C6F-BBD4-3AA29ABE9C7E

P1476

Q34656225-D1660E30-09E4-4498-8F84-52919354DB9B

P2093

Q34656225-0F66CA4A-DAC3-4294-ADCF-BDCB35F1321D

Q34656225-771D50EB-4F5F-4ECB-8533-6E5F776D6DBE

Q34656225-8A14435C-3B64-4769-AF16-4F735D60B80F

Q34656225-E8C586F2-5E1B-45AC-9D0B-BB75EDE48945

P2860

Q34656225-0D1827B0-A4B4-4BDF-A9FA-466E43695F9C

Q34656225-381ED578-5978-4CAE-8CCC-F4E6353C7E7F

Q34656225-42F8E16F-BD2B-4B82-AF87-43A7DE53927A

Q34656225-749CF240-694F-4DB7-A23C-B10A9297FE25

Q34656225-A179D0BB-06BC-4BC2-93D7-D7227B2E51E8

Q34656225-C4816C1A-EFBB-4F28-B104-7492A59A2120

Q34656225-CB63741A-FC65-40A0-8EFC-B735E4FA9E70

P2888

Q34656225-4901B3C8-27A3-4AFC-964A-F68D75C26768

P304

Q34656225-C96576AC-7D90-4DA6-90CA-2FADCD15DAD5

P31

Q34656225-89BE22C5-2D65-4A49-A852-5DB9F80D2F46

P356

Q34656225-0802DE17-48E0-48AC-9203-0FC211E173C0

P433

Q34656225-65E99453-F78B-42B3-9735-9730208CAE50

P478

Q34656225-5093ED45-25BF-4732-A6A9-10A8E53BDD55

P50

Q34656225-6FF9EF66-9FA2-4EA7-8A12-500620DC2429

Q34656225-E2FDB515-D11E-4A9D-949A-FBF883FAC158

P577

Q34656225-4D4BD12E-E2A3-4225-8761-02A6B7CE168C

P5875

Q34656225-C4E582B3-7B1D-4A0E-8840-BC9612E9235C

P6179

Q34656225-173E073E-0B3D-453A-831B-72A24E3F82BC

P698

Q34656225-D31B23E9-600F-42BB-8A3B-3023129DB45D

P356

00003088-200746080-00001

P1433

Clinical Pharmacokinetics

P1476

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

@en

P2093

Garry G Graham

http://www.w3.org/2001/XMLSchema#string

Kenneth M Williams

http://www.w3.org/2001/XMLSchema#string

Mark Hicks

http://www.w3.org/2001/XMLSchema#string

Sophie L Stocker

http://www.w3.org/2001/XMLSchema#string

P2860

Pathogenesis of Gout

Allopurinol kinetics

Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates

1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect

Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.

Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol

Anomalous parameter estimates in the one-compartment model with first-order absorption.

P2888

00003088-200746080-00001

P304

623-644

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/00003088-200746080-00001

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Andrew J. McLachlan

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233578032

http://www.w3.org/2001/XMLSchema#string

P6179

1030923360

http://www.w3.org/2001/XMLSchema#string

P698

17655371

http://www.w3.org/2001/XMLSchema#string